- AI-screener
- Securities US
- Amgen Inc.
Amgen Inc.
$289.00
-$0.37
-0.13%
18 Jun 20:00
$253.30
$346.85
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
weak bearish sentiment increases
Long
100.00%Short
0.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | — | |
Support | — | |
Cash flows | — |
Momentum
Indicators for analyzing trends in the instrument. Based on them you can choose the optimal moment to open or close a position.
Return/MDD
0.99Sentiment
BullishStart Date
05.27.2025Duration
22Yield
3.64%Avg.Yield
2.21%
Volatility
1.75%Max MDD
3.66%Avg. MDD
0.86%Min Price
RUB 278.40Max Price
RUB 297.29
Protective stop levels
S/L 5%RUB 275.55 | S/L 10%RUB 261.05 | S/L 15%RUB 246.54 | |
|---|---|---|---|
Day | 0.43% | 0.00% | 0.00% |
Week | 20.18% | 0.78% | 0.00% |
Month | 53.34% | 19.42% | 4.42% |
Technical analysis
- Trend ClassDown and flat
- Trend PowerAlmost flat
- PatternChannel
- EMA-20Bullish reversal2025-05-27 the price crossed up the moving average line and demonstrates an upside trend.
- EMA-50Bullish reversal2025-05-29 the price crossed up the moving average line and demonstrates a strong upside trend.
- EMA-100Bullish reversal2025-06-06 the price crossed up the moving average line and formed a short-term upside trend.
- StochasticBullish weakeningThe stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.
- RSIBullish RecoveryRSI indicator is in overbought territory and it grows. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.
- MACDBullishOscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: signal line crossed the middle level.
- Candle pattern typeBearish HaramiConsists of an unusually large white body followed by a small black body contained within. Large white body It is considered as a bearish pattern when preceded by an uptrend.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | -0.49% | 0.89% | $286.60 | $291.87 | 325.92M |
| Week | -1.64% | 0.90% | $286.60 | $299.49 | 1.74B |
| Month | 6.16% | 2.39% | $269.10 | $299.49 | 8.70B |
| 3 Months | -8.86% | 2.67% | $261.43 | $318.92 | 25.94B |
| 6 Months | 12.16% | 16.86% | $253.30 | $335.88 | 48.96B |
| Year | -4.45% | 0.64% | $253.30 | $346.85 | 88.75B |
| 3 years | 25.74% | 56.82% | $211.71 | $346.85 | 230.36B |
| 5 years | 23.99% | 96.86% | $198.64 | $346.85 | 385.87B |
| All time | 2,253.78% | 62.21% | $11.66 | $346.85 | 360.28B |
Volatility
| AMGN | By industry | |
|---|---|---|
| Yesterday | 2.18% | 1.09% |
| Week | 3.65% | 5.55% |
| Month | 5.64% | 12.79% |
| 3 Months | 10.56% | 22.23% |
| 6 Months | 17.23% | 29.80% |
| Year | 25.82% | 38.65% |
| 3 years | 41.45% | 81.91% |
| 5 years | 52.53% | 115.04% |
| All time | — | — |
- Sortino
- -0.08
- Sharpe
- -0.10
- Sterling
- -0.11
- Liquidity index
- 7.09
- Alpha
- 0.00015
- Beta
- 0.34
AI Factors
Drivers of growth or decline are external factors, selected using AI, that can significantly affect the price of a company's shares in the future.
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$155.74B
Capitalization
537.71M
Shares outstanding
Health Care
Sector
Biotechnology
Industry
Mr. Robert A. Bradway
CEO
Website
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.